What happened
In the CoCAP substudy of the TACSI trial, ticagrelor plus aspirin did not improve graft patency compared with aspirin alone when assessed by coronary CT angiography a mean of 20 months after CABG.
No takes yet. Share an insight, caveat, or question.
Answers are grounded in this paper and cite their sources.
Why the trial, key points, tables, limitations, PICO, abstract, media & sources
Dual antiplatelet therapy is often continued after CABG for acute coronary syndrome, but whether it actually improves graft patency compared with aspirin alone — at the cost of more bleeding — lacked solid randomised evidence.
Does ticagrelor plus aspirin improve graft patency compared to aspirin alone in patients with acute coronary syndrome after coronary artery bypass grafting?
Does ticagrelor plus aspirin improve graft patency compared to aspirin alone in patients with acute coronary syndrome after coronary artery bypass grafting?
Expert reaction
ESC Congress 2026
0 experts have reacted so far. We show the split once 3 have.
Expert labels are toward CoCAP's result, from named public quotes (n=0). As of Nov 3, 2026.
In patients with acute coronary syndrome undergoing coronary artery bypass grafting, adding ticagrelor to aspirin did not improve graft patency at 20 months compared to aspirin alone.
Discover the results from EVAOLD, ISOLEDS, CorCal and CoCap, presented on Monday, 31 August 2026.
Jonas et al. (2026) conducted an RCT in Acute coronary syndrome after coronary artery bypass grafting. Ticagrelor plus aspirin vs. Aspirin alone was evaluated on Graft patency assessed using coronary CT angiography.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: